FX.co ★ Jazz Pharma Reports Positive Topline Data From Phase 3 IMforte Maintenance Study In ES-SCLC

Jazz Pharmaceuticals plc (JAZZ) has announced promising results from the Phase 3 IMforte clinical trial concerning adults with extensive-stage small cell lung cancer (ES-SCLC).

This study aims to assess the efficacy of Zepzelca, when used in conjunction with atezolizumab, against the efficacy of atezolizumab as a standalone treatment in maintaining the condition of adults with ES-SCLC. The study's top-line results indicate that the Zepzelca and atezolizumab combination significantly enhances both overall survival (OS) and progression-free survival (PFS) when compared to the use of atezolizumab alone.

Additionally, the combination therapy was generally well-received by patients. The preliminary safety data from this ongoing trial, which is backed by Roche with financial contributions from Jazz Pharmaceuticals, aligns with the known safety profiles of Zepzelca and atezolizumab, with no new safety concerns arising from the combination therapy.

Zepzelca, already approved for treating metastatic small cell lung cancer (SCLC), is developed by PharmaMar and marketed by Jazz in the United States. Meanwhile, Roche’s immunotherapy drug atezolizumab is approved for several cancer types, including non-small cell lung cancer (NSCLC) and SCLC.

Jazz plans to file a supplemental New Drug Application for the Zepzelca and atezolizumab combination therapy as a first-line maintenance option for ES-SCLC in the first half of 2025.